Phase 2 Study of WGI-0301 for Advanced HCC

This Phase 2 study tests a new drug called WGI-0301 in patients with advanced liver cancer (hepatocellular carcinoma, or HCC) whose disease has progressed after standard treatments. The drug targets specific pathways involved in cancer cell survival. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with liver cancer (HCC), either confirmed by biopsy or through standard imaging criteria - Your liver cancer is in an advanced stage (BCLC Stage C, or Stage B with extensive liver involvement) - You have tried at least one standard treatment that did not work, or you cannot tolerate standard treatments **You may NOT be eligible if...** - You have significant liver scarring (cirrhosis) that severely impairs liver function - You are pregnant or breastfeeding - You have uncontrolled infections or other serious medical conditions - You have had a prior liver transplant Talk to your doctor to see if this trial is right for you.